Chromocell announces unveiling of injectable depot program for the treatment of surgical pain

Freehold, n.j., oct. 29, 2024 (globe newswire) -- chromocell therapeutics corporation (“chromocell”, or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. the depot program is based on the company's novel nav1.7 molecule for treating chronic pain and eye pain.
CHRO Ratings Summary
CHRO Quant Ranking